Lung Cancer Clinical Trials in Chicago

Showing 141-160 of 358 trials

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

NCT04101357

This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors.

Solid TumorExtensive-stage Small Cell Lung Cancer

BioNTech SE54 participantsStarted Jun 2020

Los Angeles, California, United States • Chicago, Illinois, United States • Greenville, South Carolina, United States +9 more locations

TERMINATEDPHASE22.2 miles

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more

Seagen Inc.205 participantsStarted Oct 2019

Chandler, Arizona, United States • Los Angeles, California, United States • Santa Rosa, California, United States +63 more locations

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Lung Cancer Trials in Other Cities

MGD019 DART® Protein in Unresectable/Metastatic Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Pulmonary Rehabilitation Before Lung Cancer Resection

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Study of LP-184 in Patients With Advanced Solid Tumors

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Avelumab in First-line NSCLC (JAVELIN Lung 100)

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Milademetan in Advanced/Metastatic Solid Tumors

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Other Conditions in Chicago